Additionally, the application of the CSN5 inhibitor curcumin inhibited the ubiquitination of PD-L1, reduced PD-L1 expression, and increased the sensitivity of tumor cells to CTLA4 immunotherapy [73]. The gene discussed is CD274; the disease is neoplasm.